Merck & Co. Inc.

06/22/2022 | Press release | Distributed by Public on 06/22/2022 04:50

U.S. FDA Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and Children